SCHEMBL25921444

SCHEMBL25921444

CC1Sc2ccc(C(=O)Nc3cccc(S(=O)(=O)Nc4cccc(Cl)c4)c3)cc2NC1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.56
▸ RAB9A P51151 5/20 0.55
▸ NPC1 O15118 4/20 0.55
▸ LMNA P02545 4/20 0.54
▸ SMN1; SMN2 Q16637 4/20 0.54
▸ MEN1 O00255 4/20 0.54
▸ MAPT P10636 3/20 0.54
▸ HTT P42858 3/20 0.54
▸ MAPK1 P28482 2/20 0.54
▸ NPSR1 Q6W5P4 2/20 0.54
▸ ALDH1A1 P00352 1/20 0.54
▸ HDAC1 Q13547 1/20 0.53
▸ HDAC8 Q9BY41 1/20 0.53
▸ HDAC6 Q9UBN7 1/20 0.53
▸ TP53 P04637 1/20 0.53
▸ PTBP1 P26599 1/20 0.52
▸ ATM Q13315 1/20 0.51
▸ POLB P06746 1/20 0.48
▸ ADORA3 P0DMS8 1/20 0.47
▸ ADORA2A P29274 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25920774 0.94 KMT2A (0.58) KMT2ARAB9ANPC1LMNASMN1; SMN2
SCHEMBL24125135 0.92 RAB9A (0.61) KMT2ARAB9ANPC1LMNASMN1; SMN2
SCHEMBL25920904 0.90 TP53 (0.62) KMT2ARAB9ANPC1LMNASMN1; SMN2
SCHEMBL25920771 0.89 KMT2A (0.56) KMT2ARAB9ANPC1LMNASMN1; SMN2
SCHEMBL25920902 0.89 KMT2A (0.59) KMT2ARAB9ANPC1LMNASMN1; SMN2
SCHEMBL25921447 0.89 KMT2A (0.58) KMT2ARAB9ANPC1LMNASMN1; SMN2
SCHEMBL25921455 0.89 SMN1; SMN2 (0.56) KMT2ARAB9ANPC1LMNASMN1; SMN2
SCHEMBL25921712 0.89 SMN1; SMN2 (0.58) KMT2ARAB9ANPC1LMNASMN1; SMN2
SCHEMBL25921738 0.87 KMT2A (0.54) KMT2ARAB9ANPC1LMNASMN1; SMN2
SCHEMBL24124837 0.87 RAB9A (0.61) KMT2ARAB9ANPC1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) 2023-08-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242496-A1 SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA BCL6, SOX18, BCL3 KMT2A 578/4885RAB9A 1163/4885NPC1 2197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback